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Introduction
During a rainy, windswept San Francisco week in mid-
December, over 8000 scientists found shelter at the 42nd
annual meeting of the American Society for Cell Biology
(ASCB) in the Moscone Convention Center. Attendees
were spoiled for choice, with a diverse array of high-quality
research ranging from bacterial environmental sensing to
the modeling of evolution. The talks ranged from excellent
plenary lectures discussing some of the most important
and exciting issues facing cell biologists today, to smaller,
more intimate minisymposia that focused on single topics
and allowed for lively discussions from a larger number of
contributors. The meeting opened on Saturday afternoon
with 24 parallel special-interest-group meetings followed
by the four keynote lectures. There were 8 major symposia
of three lectures each over the succeeding four mornings,
and a staggering total of 232 minisymposium talks in the
afternoons. These minisymposia represented an embar-
rassment of riches and it was often difficult to decide
which sessions to attend. Additionally, there were several
outstanding lectures from this year’s ASCB award-
winners, Avram Hershko, Alexander Varshavsky, Kathleen
Collins, Frank Talamantes, Benjamin Cravatt, Eric
Wieschaus, Natasha Raikhel, and Clare Waterman-Storer.
Over 3000 posters were presented, giving a large propor-
tion of the attendees the opportunity to communicate their
research to a wide and appreciative audience. This year’s
ASCB social took place in the outstanding San Francisco
Museum of Modern Art, allowing the delegates to let their
hair down, mingle, and contemplate an entirely different
set of abstractions from those on display across the street
at the Moscone Center.
It would be impossible in a brief report to attempt to com-
municate the vast depth and breadth of research pre-
sented during this meeting, so we have elected to
concentrate our efforts on discussing some of the work of
most relevance to breast cancer research. The subhead-
ings used do not directly reflect the sessions of the ASCB
meeting but were chosen to provide a meaningful frame-
work for the presentation of this research.
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Abstract
The Annual Meeting of the American Society for Cell Biology (ASCB) is a diverse conference covering
all topics in cell biology. While all of the basic biology presented at this meeting may potentially
contribute to breast cancer research, there were a significant number of presentations and posters
directly pertinent to this field. Here we have summarized the research that is of greatest immediate
relevance to breast cancer, with particular emphasis on mammary gland development and tumorigenesis
in vivo, three-dimensional in vitro models of mammary morphogenesis, alterations of signal transduction
pathways in breast cancer, and global studies in expression profiling and drug screening.
Keywords: basement membrane, breast cancer, matrix metalloproteinase, metastasis, signal transduction148
Breast Cancer Research    Vol 5 No 3 Kenny and Rizki
Mammary gland development and
tumorigenesis in vivo
Many new in vivo mouse models of mammary gland devel-
opment were presented. Roles of matrix metallo-
proteineases and other extracellularly presented or secreted
molecules such as epimorphin, cytokines, and secreted
glycoproteins, as well as multiple transcription factors, were
investigated. In addition, two reports on the stem cell com-
partment of the mouse mammary gland were presented.
Cytokines
Argentinean scientists, led by Carolina Schere-Levy
(Experimental Medicine, Academia Nacional de Medicina,
Buenos Aires, Argentina) reported their studies on the
expression of leukemia inhibitory factor (LIF) during the
developmental stages of the mouse mammary gland. LIF is
a glycoprotein and a cytokine that regulates growth and
differentiation. She and her colleagues in Edith C Kor-
don’s group showed for the first time that LIF has a role in
the involution stage of the mammary gland cycle. They
showed that expression of LIF is increased significantly
during the early stages of involution. Mechanistically, LIF
expression is induced by milk stasis. Furthermore, ectopic
expression of LIF results in increased apoptosis of the
epithelial cells. LIF expression also induces phosphoryla-
tion of Stat3, the main factor signaling initiation of apopto-
sis, thereby suggesting that LIF is upstream of Stat3
during the early stages of involution of the mouse
mammary gland [1].
Ling Zhao and colleagues (National Institutes of
Health/National Institute of Diabetes and Digestive and
Kidney Diseases, Bethesda, MD, USA) reported on the
role of the IL-6 family of cytokines in mammary gland
development. They tested the hypothesis that pathways
activated by these cytokines are necessary for activation
of Stat3 and p42/44 mitogen-activated protein kinase
(MAPK), as both of these signals are observed in the early
stages of involution. gp130 is a common receptor subunit
for the IL-6 family of cytokines such as IL-6 and LIF; there-
fore, the NIH group characterized the mammary gland
phenotypes of mice lacking either IL-6, LIF, or gp130.
First, they observed in wild-type mice that mRNA levels for
LIF and IL-6 are higher during involution than lactation, and
that this parallels activation of Stat3 and p42/44 MAPK.
Furthermore, deletion of either IL-6, LIF, or Stat3 in the
mammary gland gave delayed-involution phenotypes.
However, activation of Stat3 in early involution was
observed in the absence of either IL-6 or LIF, suggesting
that these factors are not required for Stat3 activity.
Combined with results of Schere-Levy and colleagues,
these results suggest that LIF is sufficient but not required
for Stat3 activation, i.e. LIF activity can be redundant. Acti-
vation of MAPK as well as the epithelial cell-death pheno-
type and proapoptotic gene expression that accompanies
early involution was dependent on IL-6, suggesting that
the cytokines of the IL-6 family play a role in apoptotic
events needed for mammary gland involution.
Stem cells
As recently reported [2], Gilbert Smith (National Institutes
of Health, Bethesda, MD, USA) presented interesting data
with potential relevance to the differences between the
incidence of breast cancer in women who have not given
birth and those who have. More specifically, he described
the presence of a population of cells with stem-cell-like
properties in the involuted mammary glands of parous
mice (those that had given birth) that were absent in virgin
animals. He showed that a postinvolution mammary gland
is fundamentally different from a virgin gland (that is, one
in a mouse that had never undergone pregnancy, lactation,
or involution). His evidence suggests that this difference is
primarily the result of the formation of an apoptosis-resis-
tant population of epithelial cells after the first round of
pregnancy–lactation–involution. These cells function as
the progenitors of alveolar structures in subsequent preg-
nancies. Interestingly, this epithelial cell population mani-
fests an ability to form mammary glands upon
transplantation into cleared fat pads of syngeneic immune-
compromised mice, forming ducts and lobular structures
and giving rise to all of the cellular subtypes found in
mouse mammary epithelium, including both luminal and
myoepithelial cells.
Another stem-cell-related study was presented by Bryan
Welm from Zena Werb’s laboratory (University of Califor-
nia San Francisco, San Francisco, CA, USA). This poster
built on his previous work in which cells expressing stem
cell antigen 1 were shown to be enriched for multipotent
mammary stem cells. Here, Welm and co-workers exam-
ined several transgenic models of mouse mammary
tumors and found that tumors from MMTV-Wnt-1 mice
contained significantly more cells positive for stem cell
antigen 1 than tumors from MMTV-Neu or MMTV-polyoma
middle-T mice. These data suggest that different onco-
genic lesions affect the mammary stem cell compartment
in different ways, and that overexpression of Wnt-1
induces an expansion of the progenitor cell population.
Matrix metalloproteinases
Zena Werb’s laboratory (University of California San Fran-
cisco, San Francisco, CA, USA) presented posters on the
roles of matrix metalloproteinase 14 (MMP14) (membrane-
type-1 MT1-MMP) in mammary gland development, and of
MMP9 in mammary tumorigenesis. Using grafts of
mammary glands from wild-type and MMP14-null mice
under the kidney capsules of immune-compromised mice
as an assay, Heidi Mananzan and colleagues found that
the number and the length of mammary epithelial ducts
were decreased in the absence of MMP14. In addition,
cleavage of collagen type I was greatly reduced in the149
absence of MMP14 activity. These results add MMP14 to
the ever-increasing list of MMPs and other factors that
affect mammary gland development.
Mikala Egeblad, also from Werb’s laboratory, reported an
unexpected effect of MMP9 in mouse mammary tumori-
genesis. Increased MMP9 expression in human cancers
correlates with metastasis, suggesting a role for MMP9 in
human breast cancer progression. However, in this study,
targeted deletion of MMP9 in mouse mammary models of
breast cancer such as MMTV-Neu and MMTV-Wnt-1
resulted in increased tumorigenesis. An understanding of
the mechanisms underlying such results could shed light
on the unexpectedly low success rate of MMP inhibition in
clinical trials for cancer treatment [3].
Previous collaborative work between members of the
Werb laboratory and of Mina Bissell’s laboratory
(Lawrence Berkeley National Laboratory, Berkeley, CA,
USA) showed that transgenic mice overexpressing MMP3
(stromelysin-1) exhibited increased mammary tumorigene-
sis [4]. Additionally, treatment of nonmalignant mammary
epithelial cells (Scp2) with MMP3 induced scattering and
expression of mesenchymal cell markers, as well as cleav-
age of E-cadherin [5]. Jimmie Fata and colleagues
reported that this epithelial–to–mesenchymal transition is
also observed with MMP9 but not with MMP2, MMP7, or
MT1-MMP. In addition, they described an assay that is
currently under development to ask if E-cadherin cleavage
is necessary for epithelial–to–mesenchymal transition, and
therefore for acquisition of malignancy.
Epimorphin
Epimorphin/syntaxin 2 has been reported to induce
branching morphogenesis of cultured mammary epithelial
cells [6]. Following up on these observations, members of
the Bissell laboratory (Lawrence Berkeley National Labora-
tory, Berkeley, CA, USA) presented studies on the role of
epimorphin in mammary gland development. Jamie
Bascom described a transgenic mouse model, expressing
epimorphin (with an IL-2 signal peptide for cell-surface
expression) from a mammary-specific WAP (whey acidic
protein) promoter. They reported that epimorphin can
indeed perturb mammary gland development in vivo. The
main features of the developmental phenotype include
precocious lobuloalveolar development, thicker ducts, and
extensive lateral branching, in addition to a delayed-involu-
tion phenotype. Bascom and colleagues also examined
epimorphin expression during wild-type gland develop-
ment and found its expression levels increased during
ductal development as well as during pregnancy. These
data support a role for epimorphin in mammary gland
branching morphogenesis in vivo.
Simone Bennett and Derek Radisky from the Bissell labo-
ratory described the structure–activity relationships of
epimorphin. By using mutational analysis and molecular
modeling to compare epimorphin/syntaxin 2 to the well-
studied and highly homologous syntaxin 1A, they identified
the helical domain in which the activity of epimorphin
resides and showed that mutagenesis of a homologous
three-helix bundle affects the activity of the molecule and
its presentation at the cell surface.
Tumor suppressors, oncogenes, and signaling
pathways
Exciting data were presented about additional roles for the
p53 tumor suppressor, the identification of novel down-
stream targets of c-Myc and further analysis of many of the
signaling pathways relevant to mammary development and
tumorigenesis, including the phosphoinositide 3-kinase
(PI3K) pathway, epidermal growth factor receptor (EGFR)
signaling, molecules signaling cell–cell interaction such as
cadherins, and many others. Here we present a selected
set of breast-cancer-relevant studies relating to tumor sup-
pressors, oncogenes, and signaling pathways.
p53
Martha Stampfer, Paul Yaswen, and colleagues
(Lawrence Berkeley National Laboratory, Berkeley, CA,
USA), in collaboration with Thea Tlsty (University of Cali-
fornia San Francisco, San Francisco, CA, USA), pre-
sented their work on the effect of p53 on senescence
and immortalization of mammary epithelial cells in vitro.
Cell immortalization is a necessary step in tumorigenesis.
Long-term collaborative work of Stampfer, Tlsty, and
Yaswen has resulted in the hypothesis that there is an
M1/senescence/selection barrier, followed by a second
barrier, called agonescence, which human mammary
epithelial cells (HMECs) need to overcome in order to
become immortal. It has been shown that abrogation of
the Rb pathway can remove the first block, and the re-
acquisition of telomerase activity can overcome the
second block, to allow immortalization. Here they investi-
gated the role of the p53 pathway in agonescent and
postagonescent HMECs. They reported that if agones-
cence is approached with nonfunctional p53, then crisis,
rather than agonescence, occurs. In addition, inactivating
p53-dependent cell-cycle checkpoints results in a similar
crisis phenotype in these HMECs. These data led
Stampfer and colleagues to suggest that most cultured
cell lines arrest at the first barrier of senescence and that
crisis does not occur when the p53 pathway is functional.
In cells that have overcome both senescence and
agonescence by chemical carcinogen treatment, p53
activity in the cells slows down the process of telomerase
reactivation and acquisition of uniform cell growth, both
of which are required for cell immortalization. Since most
human cancers are p53-deficient, the results of Stampfer
and colleagues with HMECs in vitro suggest new roles
for p53 in tumorigenesis, including the potential for
telomerase reactivation.
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Another role for p53 in tumorigenesis was explored by
Wilma Lingle (Mayo Clinic, Rochester, MN, USA) and col-
leagues, who investigated the effects of various p53 muta-
tions on centrosome structure and function. Centrosome
amplification has been proposed to play a role in chromo-
somal instability, aneuploidy, and tumor progression. Build-
ing on previous work which showed that tumors lacking
functional p53 have a significantly greater microtubule
nucleation capacity than tumors with wild-type p53, Lingle
and her co-workers studied the effects of two tumor-
derived p53 mutants in cultured breast epithelial cells.
They showed that the frequency of multipolar mitoses and
the in vivo microtubule regrowth rate depend on the spe-
cific p53 mutation, indicating that centrosomal homeosta-
sis is differentially sensitive to distinct p53 mutations.
c-Myc
c-Myc has been extensively studied for its roles in prolifer-
ation, differentiation, and apoptosis, and many putative
downstream targets have been identified. Despite this,
many of the transcriptional target genes that act as effec-
tors of c-Myc-induced phenotypes have yet to be identi-
fied. Alexander Swarbrick and co-workers (Garvan
Institute of Medical Research, Sydney, Australia) reported
that Id1 may be a critical target of c-Myc in breast cancer
cells. They demonstrated this by studying the effects of
both inducible overexpression and loss of c-Myc function
on the expression of Id1 in the human breast carcinoma
cell lines T47D and MCF-7, and in the mouse mammary
epithelial cell line HC11. Id, a helix–loop–helix transcrip-
tion factor that has recently been implicated in mammary
epithelial cell proliferation, differentiation, and tumorigene-
sis, is rapidly induced upon c-Myc overexpression. Cells
pretreated with antisense oligonucleotides to Id1 failed to
proliferate after c-myc induction. These experiments show
that Id is a downstream target of c-Myc in breast cancer
cell lines and may be an important mediator of c-Myc phe-
notypes in breast cells.
Oncogenic signaling
Wan-Nan Chen and Brian Thrall (Pacific Northwest
National Laboratory, Richland, WA, USA) presented their
findings on the relationship between the EGFR autocrine
signaling and tumor necrosis factor alpha (TNF-α) activity
in HMECs. TNF-α is commonly associated with the inhibi-
tion of proliferation in mammary cancer cells, whereas
EGFR transmits proliferation signals. Using normal
HMECs (HMEC184A1), Chen and Thrall showed that low
concentrations of TNF-α induce cell proliferation and
migration in this model. These effects were sensitive to
inhibitors of EGFR. TNF-α treatment stimulated the secre-
tion of MMP9, and treatment of the cells with an MMP
inhibitor blocked TNF-α-induced cell migration.
Dinah Levy and colleagues from the Bissell laboratory
(Lawrence Berkeley National Laboratory, Berkeley, CA,
USA) reported the effects of isoforms of c/EBPβ (CCAAT
enhancer binding protein beta) in epithelial–to–mesenchy-
mal transition in mouse mammary epithelial cells. This
protein is essential for normal mammary gland morpho-
genesis. Two antagonistic isoforms, liver-enriched
inhibitory protein (LIP) and liver-enriched activator protein
(LAP), are expressed from c/EBPβ. The ratio of these iso-
forms changes throughout development and is altered in
breast cancer. Normal mammary epithelial cells respond
to laminin-rich basement membrane by increasing the
LAP/LIP ratio, a response that is lost in tumor cells. Levy
addressed the functional consequence of altering the
LAP/LIP ratio in cultured malignant mouse mammary
epithelial cells. Overexpression of LAP in these tumor cells
resulted in a partial reversion of the malignant phenotype,
with reorganization of tight junctions and acquisition of
epithelial-like morphology.
The role of cadherins in an in vivo mouse model of meta-
stasis was investigated by Vladimir Krutovskikh and co-
workers (International Agency for Research on Cancer,
Lyon, France). A cadherin-negative highly metastatic
human breast cancer cell line, SKBR3, was transfected
with constructs expressing either E- or N-cadherin.
E-cadherin expression reduced the number of metastatic
nodules detected in the axillary lymphatic glands.
N-cadherin expression increased both the number and
size of metastases in this model. Interestingly, a synergis-
tic effect on metastasis was observed when E- and
N-cadherin-expressing cells were coinoculated.
The role of the PI3K/Akt-signaling pathway in mammary
morphogenesis was a common thread that ran through a
number of posters. Akt is recruited to the membrane by
binding to phosphatidylinositol 3,4,5-phosphate moieties
generated by PI3K, and, once recruited, it is activated by
phosphorylation at Thr308 and Ser473. The Thr308
kinase has been identified as PDK1, but as yet the identity
of the kinase responsible for Ser473 phosphorylation has
remained elusive. Chohren Partovian (Dartmouth Medical
School, Hanover, NH, USA) presented some interesting
data suggesting that this PDK2 activity is actually protein
kinase C alpha. Protein kinase C alpha phosphorylates
Ser473 in vitro, and siRNA-mediated down-regulation of
this enzyme in endothelial cells attenuated the activity of
Akt in response to insulin-like growth factor-1.
Models of mammary gland morphogenesis and
tumorigenesis in extracellular matrix in vitro
A plethora of presentations using three-dimensional extra-
cellular matrix models of mammary acini pointed to the
beginning of a new era in breast cancer research.
Pioneered by Mina Bissell (Lawrence Berkeley National
Laboratory, Berkeley, CA, USA) and Ole Petersen (Panum
Institute, Copenhagen, Denmark) about a decade ago [7],
three-dimensional cultures of mammary epithelial cells are
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now gaining widespread appreciation as physiologically
relevant models for in vitro studies. The Bissell and
Petersen laboratories described the use of laminin-rich
basement membrane (Matrigel) cultures of nonmalignant
and malignant mammary epithelial cells of the HMT-3522
tumor progression series [4,7]. The growth of the non-
malignant cells was arrested after they had formed polar-
ized acinar structures resembling mammary acini in vivo.
Conversely, the growth of tumorigenic counterparts of
these cells failed to be arrested in basement membrane
cultures and the cells formed disorganized, nonpolarized
colonies.
MCF10A mammary acini
Using similar paradigms but a different cell model, the
members of Joan Brugge’s laboratory (Harvard Medical
School, Boston, MA, USA) presented an excellent series
of posters and talks on their recent work on the morpho-
genesis of MCF10A mammary acini in vitro  [8]. When
grown in three-dimensional culture, MCF10A cells form
polarized acini with a hollow lumen that is formed by the
death of luminal cells. Loss of survival signals from extra-
cellular matrix is a critical regulator of luminal cell apopto-
sis. Mauricio Reginato, Kenna Mills, and colleagues
working in Brugge’s laboratory investigated the mecha-
nisms involved in the clearance of these cells to form a
hollow lumen. Using a candidate-gene approach, they
identified two proapoptotic factors, Bim and TRAIL, that
are up-regulated at different times during morphogenesis.
They showed that Bim, a proapoptotic member of the
Bcl2 family, is highly up-regulated upon cell detachment
from the extracellular matrix. Overexpression of oncogenes
such as ERBB2 can inhibit this anoikis, and overexpres-
sion of EGFR blocks the induction of Bim. Activated
alleles of Ras, Raf, and MEK also block Bim up-regulation,
implicating this pathway downstream of EGFR. Inhibition
of Bim using siRNA delays the apoptotic clearance of the
lumen. The expression of Bim is suppressed by signals
from the extracellular matrix via β1-integrin and MEK. Inter-
estingly, Bim was expressed throughout the acinar struc-
ture, while only the luminal cells underwent apoptosis; this
observation suggests that these cells are differently sensi-
tive to the death signal. Inhibition of TRAIL at this time
point had no effect, but at later time points, dominant-neg-
ative TRAIL blocked the apoptosis of cells that repopulate
the lumen later in morphogenesis. Mills presented a model
in which Bim and TRAIL mediate two distinct phases of
apoptosis during luminal morphogenesis.
Carolyn Wrobel and colleagues from the Brugge labora-
tory probed the effects of the colony-stimulating-factor-1
receptor (CSF-1R) signaling pathway in the MCF10A
acinar morphogenesis model. In cells transfected with this
receptor tyrosine kinase, treatment with its ligand, CSF1,
induced normal morphogenesis, suggesting that the
CSF-1/CSF-1R pathway can substitute for the interaction
between epidermal growth factor (EGF) and EGFR in pro-
moting morphogenesis. Overactivation of this pathway,
either with high levels of ligand or a constitutively active
mutant of the CSF-1R, induced hyperproliferation, dis-
rupted morphogenesis, and prevented the formation of a
hollow lumen. The use of pharmacological inhibitors sug-
gested that the effects of CSF1 in this system require the
activities of both Src and matrix metalloproteinases.
Jayanta Debnath, also from the Brugge laboratory, investi-
gated the role of the PI3K/Akt signaling pathway in the for-
mation of the acinar lumen. Using phosphospecific
antibodies, they detected active Akt only in the polarized
outer cells of these acini. Expression of a constitutively
active Akt throughout the acinus resulted in large, irregular,
apolar acini. Although all cells were expressing active Akt,
significant luminal apoptosis still occurred. Akt could coop-
erate with proliferative oncogenes such as cyclin D1 to
promote morphogenesis independently of EGF. Inhibition
of mTOR (mammalian target of rapamycin), a downstream
effector of the PI3K/Akt pathway, blocked the effects of
Akt on morphogenesis and oncogene-driven proliferation.
HMT-3522 mammary acini
Johanne Le Beyec and Sun-Young Moonlee, from the
Bissell laboratory, reported exciting findings on the role of
alteration of cell shape on histone acetylation in non-
malignant breast epithelial cells of the HMT-3522 series.
When grown in laminin-rich basement membrane, non-
malignant breast epithelial cells underwent growth arrest
and formed polarized acini. Le Beyec and colleagues
reported that this differentiation was accompanied by a
global deacetylation of histone H4. They went on to show
that this reduction is not related either to growth arrest or
to signal transduction pathways activated by the extracellular
matrix. Acini cultured in basement membrane constituents
differed from monolayer cultures at multiple levels, includ-
ing extracellular-matrix–cell interactions, cell–cell inter-
actions, and changes in cell shape. The authors explored
the effect of cell shape alterations either by removing EGF
from monolayer cultures or by growing cells on polyHEMA
– an inert substrate that allows cell rounding without the
addition of any extracellular matrix component. In both
cases, a reduction in histone H4 acetylation levels was
observed. This cell-rounding effect was shown to be asso-
ciated with actin microfilament assembly, since disrupting
them in monolayer cultures, using cytochalasin D, reversibly
decreased acetylated histone H4 levels. Cumulatively,
these results suggest mechanisms by which breast tissue
may achieve specificity of gene expression and nuclear
organization.
Collaborators from the laboratories of Bissell, Petersen, and
Weaver described the isolation and characterization of
three additional cell lines with phenotypes intermediate
between the nontumorigenic and tumorigenic counterparts
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of the HMT-3522 mammary epithelial cell series. The newly
isolated ‘premalignant’ cell lines form disorganized colonies
in basement membrane cultures but are neither invasive nor
tumorigenic. The ability to study the interrelationships
between polarity, invasiveness, and tumorigenicity in a
series of cell lines of identical genetic origin provides tools
for the identification of genes that contribute to such pheno-
types. Aylin Rizki, Valerie Weaver, and colleagues reported
on global studies of the genome and gene expression pro-
files of the nonmalignant, premalignant, and malignant
members of this tumor progression series and proposed
genes whose function may be relevant to the in vivo loss of
polarity and invasiveness of mammary tumors.
Using the HMT-3522 model, Gabriela Rozenberg and
co-workers (University of Pennsylvania, Philadelphia, PA,
USA) found that expression of both fibronectin and its
receptor, α5β1 integrin, correlated with the malignant phe-
notype. Interestingly, both of these factors are down-regu-
lated upon pharmacological reversion of malignancy in
these cells. These workers found that expression of wild-
type α5 integrin disrupted the polarity of the nonmalignant
cells if fibronectin was provided as a substrate in the
basement membrane cultures and that a dominant nega-
tive α5 integrin could repress the invasiveness and restore
the polarity of the malignant cells. These findings provide
additional insight into the role of fibronectin–integrin inter-
actions in the regulation of breast tissue function.
Other basement membrane models
Few good models exist for the study of the endogenous
estrogen receptor in cultured, functionally normal
mammary epithelial cells. Virginia Novaro and colleagues
from the Bissell laboratory showed that culturing such cells
in laminin-rich basement membrane could maintain func-
tional expression of estrogen receptor alpha (ER-α), which
is usually lost when cells are cultured on two-dimensional
plastic substrata. They showed that this effect is elicited
by two components of the extracellular matrix: collagen
type IV and laminin 1. The effects of collagen type IV are
mediated via its interaction with α2 and β1 integrins, while
regulation of ER-α via laminin 1 is mediated by α2, α6, and
β1 integrins. These data provide further evidence for the
role of the extracellular matrix in maintaining the form and
function of the mammary gland.
Loss of p53 function is a common feature of breast and
other cancers. Victoria Seewaldt and colleagues (Duke
University, Durham, NC, USA) investigated the conse-
quences of acute suppression of p53 in normal, nonimmor-
talized HMECs in vitro. In these authors’ model, the
mammary cells proliferated in reconstituted basement
membrane for 6 days and formed growth-arrested acini by
day 7. Suppression of p53 function, by the use of either
antisense oligonucleotides or retrovirally expressed E6
protein, triggered apoptosis on day 7 in this model. This
apoptosis was induced by the laminin component of recon-
stituted basement membrane and was inhibited by antibod-
ies that block the function of either α3 or β1 integrin [9].
Adhesion to the extracellular matrix is required for the sur-
vival of epithelial cells. Andrew Gilmore and colleagues
(University of Manchester, Manchester, UK) investigated
the effects of blocking this adhesion on the localization of
the proapoptotic Bcl2-family member Bax. Bax is typically
localized in the cytoplasm, but apoptotic stimuli promote
its translocation to the mitochondrial membrane. A subse-
quent reorganization of Bax into clusters at the mitochon-
drial membrane stimulates the release of cytochrome c.
When mammary epithelial cells were detached from extra-
cellular matrix and cultured on polyHEMA (thereby block-
ing the activation of integrins), Bax translocated to the
mitochondrial membrane within 15 minutes. Formation of
supramolecular Bax clusters was a later event that corre-
lated with cytochrome c release.
Global strategies for understanding breast
cancer
In the special-interest group ‘Systems Biology and the Cell:
Are There Simple Rules Governing Complexity?’, Therese
Sorlie described her work on the subclassification of breast
tumors by identifying a ‘molecular portrait’ of various tumor
types and the correlation of these expression patterns with
clinical parameters such as survival and the likelihood of
metastasis. Using a hierarchical clustering approach, Sorlie
and colleagues stratified their samples into five broad
groups: basal-cell-like, ERBB2-positive, normal-breast-like,
luminal subtype A, and luminal subtype B. Both luminal sub-
types were positive for expression of ER-α but, interestingly,
these groups of ER-α-positive tumors had distinct clinical
outcomes. Tumors of the luminal subtype A class were
associated with the longest survival, whereas tumors of
both the ERBB2+ and basal subtypes had the poorest
prognosis [10]. Significantly, analysis of other breast tumor
microarray datasets [11,12] using these molecular signa-
tures extended the validity of these findings and provided
additional information. Both the ERBB2+ and basal sub-
types had significantly more metastases than the luminal A
subtype. This increase in metastases correlated strongly
with both ER-α negativity and mutations in TP53 in the
ERBB2+ and basal subtypes. These data can be accessed
via the Stanford Breast Cancer Genomics Consortium
(http://genome-www.stanford.edu/breast_cancer/).
An international team comprising three groups (Rigel Inc,
South San Francisco, CA, USA; University of Alberta,
Edmonton, Canada; and JJPRD, Beerse, Belgium)
reported a new systematic approach for the identification
of small protein sequences that can inhibit the growth of
tumor cells. Yasumichi Hitoshi and colleagues used a
retroviral library of random 20-mer peptides fused to green
fluorescent protein to screen for growth-inhibiting pep-
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tides. They described two peptides identified in this
screen that induce arrest of the cell cycle at G0/G1 or
G2/M and are localized to the cell membrane. They went
on to show that the cell-cycle-arrest phenotype is indepen-
dent of the origin of the cell line (they tested cell lines from
breast, lung, cervical, and colon cancer) and is indepen-
dent of p53 function. They are currently identifying the
binding partners of these peptides in the cell in an effort to
identify the signaling pathways that are inhibited by them.
Global approaches such as this are likely to yield promis-
ing drug targets for breast cancer therapy.
Conclusion
The abstracts for each talk and poster presentation have
been published as a supplement to the Nov 2002 issue
of  Molecular Biology of the Cell [13] and are freely
searchable on line (http://www.ascb.org/meetings/
am2002/itinerarystart.htm).
In summary, this was a hugely enjoyable, varied, and infor-
mative meeting and we look forward to the 43rd annual
meeting of the ASCB, which will again take place in San
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